| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Russell H Swerdlow | |
| P2860 | cites work | Imaging beta-amyloid burden in aging and dementia. | Q48168226 |
| Periventricular white matter lucencies in senile dementia of the Alzheimer type and in normal aging | Q48224595 | ||
| Alzheimer neuropathologic alterations in aged cognitively normal subjects | Q48226793 | ||
| Mitochondrial enzyme expression in the hippocampus in relation to Alzheimer-type pathology | Q48234691 | ||
| Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease | Q48266934 | ||
| Abnormalities of mitochondrial enzymes in Alzheimer disease | Q48320241 | ||
| Origin of the distinction between Alzheimer's disease and senile dementia: How history can clarify nosology | Q22241642 | ||
| Alzheimer Disease in the US Population | Q22253055 | ||
| Premature ageing in mice expressing defective mitochondrial DNA polymerase | Q24294365 | ||
| Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Q24595802 | ||
| The clinical use of structural MRI in Alzheimer disease | Q24609648 | ||
| Spatial correlation between brain aerobic glycolysis and amyloid-β (Aβ ) deposition | Q24631814 | ||
| Regional aerobic glycolysis in the human brain | Q24631922 | ||
| Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle | Q24644961 | ||
| Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease | Q27860795 | ||
| The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics | Q27860914 | ||
| Mild cognitive impairment: clinical characterization and outcome | Q28140626 | ||
| Food for thought: challenging the dogmas | Q28182087 | ||
| Insights into the ageing mind: a view from cognitive neuroscience | Q28239895 | ||
| Linguistic ability in early life and cognitive function and Alzheimer's disease in late life. Findings from the Nun Study | Q28276429 | ||
| Clinical, pathological, and neurochemical changes in dementia: A subgroup with preserved mental status and numerous neocortical plaques | Q29028192 | ||
| Longitudinal Magnetic Resonance Imaging Studies of Older Adults: A Shrinking Brain | Q47950183 | ||
| Neuropathology of cognitively normal elderly | Q48125911 | ||
| Mixed brain pathologies account for most dementia cases in community-dwelling older persons | Q48136681 | ||
| Alzheimer's disease: the amyloid cascade hypothesis | Q29547160 | ||
| The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Q29547554 | ||
| Mitochondria, oxidants, and aging | Q29547594 | ||
| The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Q29614406 | ||
| Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade | Q29614407 | ||
| Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria | Q29614408 | ||
| A beta oligomers - a decade of discovery | Q29615152 | ||
| Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging | Q29616056 | ||
| Amyloid deposition as the central event in the aetiology of Alzheimer's disease | Q29619450 | ||
| Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization | Q29620724 | ||
| Alzheimer's disease cybrids replicate beta-amyloid abnormalities through cell death pathways | Q30305940 | ||
| Mitochondria in Alzheimer's disease | Q30310386 | ||
| Memory Aging From 18 to 80 | Q30311854 | ||
| A "mitochondrial cascade hypothesis" for sporadic Alzheimer's disease | Q30433751 | ||
| Pathogenesis of Alzheimer's disease | Q30439489 | ||
| Is aging part of Alzheimer's disease, or is Alzheimer's disease part of aging? | Q30441141 | ||
| Mitochondria in cybrids containing mtDNA from persons with mitochondriopathies | Q30442688 | ||
| Cytochrome c oxidase in Alzheimer's disease brain: purification and characterization | Q30465592 | ||
| Secondary inhibition of 2-ketoglutarate dehydrogenase complex by MPTP. | Q30472627 | ||
| Cellular mechanisms of brain energy metabolism and their relevance to functional brain imaging. | Q30580992 | ||
| Healthy aging and dementia: findings from the Nun Study | Q30981106 | ||
| Progression of cerebral white matter lesions -- clinical and radiological considerations | Q33275442 | ||
| Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease | Q33560183 | ||
| Alzheimer's-type neuropathology in the precuneus is not increased relative to other areas of neocortex across a range of cognitive impairment | Q33730222 | ||
| Functional expressions of the aging brain | Q33751757 | ||
| Cognition, aging, and disabilities: conceptual issues | Q33875434 | ||
| The Alzheimer's disease mitochondrial cascade hypothesis | Q33905871 | ||
| Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). | Q33935314 | ||
| Mild cognitive impairment represents early-stage Alzheimer disease | Q33938635 | ||
| High aggregate burden of somatic mtDNA point mutations in aging and Alzheimer's disease brain | Q33957039 | ||
| History of dementia and dementia in history: an overview | Q34067206 | ||
| Current concepts in mild cognitive impairment | Q34104314 | ||
| Ageing of the brain | Q34116321 | ||
| Telomere dysfunction induces metabolic and mitochondrial compromise. | Q34163637 | ||
| Correlation of brain amyloid with “aerobic glycolysis”: A question of assumptions? | Q34200085 | ||
| Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease | Q34247849 | ||
| Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain. | Q34343198 | ||
| Mitochondrial DNA deletions in human brain: regional variability and increase with advanced age | Q48403808 | ||
| Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease | Q48442778 | ||
| Brain Cytochrome Oxidase in Alzheimer's Disease | Q48453334 | ||
| White matter lesions on magnetic resonance imaging in clinically diagnosed Alzheimer's disease. Evidence for heterogeneity | Q48471565 | ||
| Reduced steady-state levels of mitochondrial RNA and increased mitochondrial DNA amount in human brain with aging | Q48516310 | ||
| Worker functions and traits associated with occupations and the development of AD. | Q48529502 | ||
| Age, neuropathology, and dementia | Q48597534 | ||
| Prevalence, incidence and duration of Braak's stages in the general population: can we know? | Q48662137 | ||
| Morphometry of the human cortex cerebri and corpus striatum during aging | Q48692899 | ||
| Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. | Q48801542 | ||
| Heterogeneity of white matter hyperintensities in Alzheimer's disease: post-mortem quantitative MRI and neuropathology. | Q48876836 | ||
| Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study | Q48958955 | ||
| Cerebrospinal fluid biomarkers and memory present distinct associations along the continuum from healthy subjects to AD patients. | Q51029739 | ||
| Evidence that age-associated memory impairment is not a normal variant of aging. | Q51966117 | ||
| "Preclinical" AD revisited: neuropathology of cognitively normal older adults. | Q51975129 | ||
| The course of cognitive impairment in preclinical Alzheimer disease: three- and 6-year follow-up of a population-based sample. | Q51976473 | ||
| Prodromal cognitive signs of dementia in 85-year-olds using four sources of information. | Q51985952 | ||
| Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 1. | Q52004978 | ||
| The preclinical phase of alzheimer disease: A 22-year prospective study of the Framingham Cohort. | Q52026279 | ||
| Aging-associated cognitive decline. Working Party of the International Psychogeriatric Association in collaboration with the World Health Organization. | Q52030106 | ||
| Cognitive decline in ageing: are AAMI and AACD distinct entities? | Q52032655 | ||
| Cognitive impairment in preclinical Alzheimer's disease: a meta-analysis. | Q52042753 | ||
| Neuropsychological detection and characterization of preclinical Alzheimer's disease. | Q52053210 | ||
| Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. | Q52112673 | ||
| Mitochondrial DNA damage as a mechanism of cell loss in Alzheimer's disease. | Q53237145 | ||
| Prevalence of Alzheimer's disease in very elderly people: a prospective neuropathological study. | Q53242647 | ||
| Hippocampal neurons in pre-clinical Alzheimer's disease. | Q53263608 | ||
| Incidence of dementia in very elderly individuals: a clinical, neuropathological and molecular genetic study. | Q53274420 | ||
| Revising the definition of Alzheimer's disease: a new lexicon. | Q53313597 | ||
| White matter lesions are prevalent but differentially related with cognition in aging and early Alzheimer disease. | Q53376124 | ||
| DNA replication fidelity with 8-oxodeoxyguanosine triphosphate. | Q54635362 | ||
| Mitochondrial bioenergetics in aging | Q57009682 | ||
| Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease | Q57132920 | ||
| [11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease | Q60451990 | ||
| Aging and mitochondria | Q60532163 | ||
| Cytochrome oxidase deficiency in Alzheimer's disease | Q68471430 | ||
| Mitochondrial DNA mutations as an important contributor to ageing and degenerative diseases | Q69368213 | ||
| Beta A4 deposits are constant in the brain of the oldest old: an immunocytochemical study of 20 French centenarians | Q70700570 | ||
| Increased risk of dementia in mothers of Alzheimer's disease cases: evidence for maternal inheritance | Q71265392 | ||
| Histopathologic correlates of white matter changes on MRI in Alzheimer's disease and normal aging | Q72227419 | ||
| Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative | Q72403715 | ||
| Neuropathological findings in the very old. Results from the first 101 brains of a population-based longitudinal study of dementing disorders | Q73808495 | ||
| No disease in the brain of a 115-year-old woman | Q81410464 | ||
| Preclinical Alzheimer disease: neuropsychological test performance 1.5 to 8 years prior to onset | Q34553815 | ||
| Cognitive decline in prodromal Alzheimer disease and mild cognitive impairment | Q35000996 | ||
| The fidelity of the human leading and lagging strand DNA replication apparatus with 8-oxodeoxyguanosine triphosphate | Q35004473 | ||
| Mild cognitive impairment, dementia, and their subtypes in oldest old women | Q35024617 | ||
| Reduced Posterior Cingulate Mitochondrial Activity in Expired Young Adult Carriers of the APOE ε4 Allele, the Major Late-Onset Alzheimer's Susceptibility Gene | Q35072027 | ||
| Impaired platelet mitochondrial activity in Alzheimer's disease and mild cognitive impairment | Q35781535 | ||
| Reduced mitochondria cytochrome oxidase activity in adult children of mothers with Alzheimer's disease | Q35795672 | ||
| Effect of apolipoprotein E allele epsilon4 on the initial phase of amyloid beta-protein accumulation in the human brain | Q35829722 | ||
| Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment | Q35868499 | ||
| Mitochondria and cell bioenergetics: increasingly recognized components and a possible etiologic cause of Alzheimer's disease | Q35898628 | ||
| Dementia incidence continues to increase with age in the oldest old: the 90+ study | Q36066005 | ||
| The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort | Q36306445 | ||
| Mitochondrial alterations in Alzheimer's disease | Q36549402 | ||
| The mitochondrial energy transduction system and the aging process | Q36614262 | ||
| Morphological substrates of cognitive decline in nonagenarians and centenarians: a new paradigm? | Q36736545 | ||
| Frequent amyloid deposition without significant cognitive impairment among the elderly | Q37085957 | ||
| Brain mitochondrial dysfunction in aging | Q37141862 | ||
| APOE epsilon2 is associated with intact cognition but increased Alzheimer pathology in the oldest old. | Q37155545 | ||
| Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease | Q37181302 | ||
| Longitudinal study of CSF biomarkers in patients with Alzheimer's disease | Q37254705 | ||
| The Alzheimer's disease mitochondrial cascade hypothesis: an update | Q37261159 | ||
| Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment | Q37415283 | ||
| Prodromal Alzheimer's disease: successive emergence of the clinical symptoms | Q38385065 | ||
| Age-associated memory impairment: diagnostic criteria and treatment strategies. | Q39492164 | ||
| Staging of Alzheimer's disease-related neurofibrillary changes | Q40416705 | ||
| Neuropsychological prediction of dementia and the absence of dementia in healthy elderly persons | Q41023468 | ||
| Mitochondrial genetics: a paradigm for aging and degenerative diseases? | Q41112226 | ||
| The neuropathological changes associated with normal brain aging | Q41225416 | ||
| Genetic and functional changes in mitochondria associated with aging | Q41441333 | ||
| The effects of perturbed energy metabolism on the processing of amyloid precursor protein in PC12 cells | Q41924922 | ||
| Amyloid-beta dynamics correlate with neurological status in the injured human brain | Q42241419 | ||
| Effect of energy shortage and oxidative stress on amyloid precursor protein metabolism in COS cells. | Q42444033 | ||
| Oxidative metabolism in cultured fibroblasts derived from sporadic Alzheimer's disease (AD) patients | Q42448361 | ||
| Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging | Q43062420 | ||
| Mitochondrial abnormalities in Alzheimer's disease. | Q43581697 | ||
| 2011 Alzheimer's disease facts and figures | Q44040789 | ||
| Oxidative stress increases expression and activity of BACE in NT2 neurons | Q44149275 | ||
| Neuropathological background of twenty-seven centenarian brains | Q44991568 | ||
| Neuropsychological tests accurately predict incident Alzheimer disease after 5 and 10 years | Q45250798 | ||
| Synaptic proteins, neuropathology and cognitive status in the oldest-old. | Q45983897 | ||
| Prevalence of dementia after age 90: results from the 90+ study. | Q46067321 | ||
| Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease | Q46956885 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Alzheimer's disease | Q11081 |
| P1104 | number of pages | 10 | |
| P304 | page(s) | 1630-1639 | |
| P577 | publication date | 2011-09-02 | |
| P1433 | published in | Biochimica et Biophysica Acta | Q864239 |
| P1476 | title | Brain aging, Alzheimer's disease, and mitochondria | |
| P478 | volume | 1812 |
| Q37691518 | A Comparative White Matter Study with Parkinson's disease, Parkinson's Disease with Dementia and Alzheimer's Disease |
| Q51760887 | A Long Journey into Aging, Brain Aging, and Alzheimer's Disease Following the Oxidative Stress Tracks. |
| Q38814123 | A Mitochondrial Role of SV2a Protein in Aging and Alzheimer's Disease: Studies with Levetiracetam |
| Q64073329 | A comparison of the mitochondrial proteome and lipidome in the mouse and long-lived Pipistrelle bats |
| Q51737097 | A key role for MAM in mediating mitochondrial dysfunction in Alzheimer disease. |
| Q37220763 | A novel bi-level meta-analysis approach: applied to biological pathway analysis |
| Q52320281 | A novel histochemistry assay to assess and quantify focal cytochrome c oxidase deficiency. |
| Q26781560 | A review on mitochondrial restorative mechanism of antioxidants in Alzheimer's disease and other neurological conditions |
| Q37618817 | Abnormal interaction of oligomeric amyloid-β with phosphorylated tau: implications to synaptic dysfunction and neuronal damage |
| Q42465030 | Age-Dependent Effect of β-Amyloid Toxicity on Basal Forebrain Cholinergic Neurons and Inflammation in the Rat Brain |
| Q34359099 | Age-dependent modulation of synaptic plasticity and insulin mimetic effect of lipoic acid on a mouse model of Alzheimer's disease. |
| Q38872085 | Alzheimer's Disease: From Mitochondrial Perturbations to Mitochondrial Medicine |
| Q37302845 | Amyloid beta-induced glycogen synthase kinase 3β phosphorylated VDAC1 in Alzheimer's disease: implications for synaptic dysfunction and neuronal damage |
| Q33599047 | Amyloid burden and neural function in people at risk for Alzheimer's Disease |
| Q34126021 | An evaluation of MSDC-0160, a prototype mTOT modulating insulin sensitizer, in patients with mild Alzheimer's disease. |
| Q43927628 | Antioxidant and cholinesterase inhibitory activity of a new peptide from Ziziphus jujuba fruits |
| Q37589456 | Association between Mitofusin 2 Gene Polymorphisms and Late-Onset Alzheimer's Disease in the Korean Population. |
| Q28542628 | Biochemical assessment of precuneus and posterior cingulate gyrus in the context of brain aging and Alzheimer's disease |
| Q26822410 | Bioenergetic dysfunction and inflammation in Alzheimer's disease: a possible connection |
| Q37686246 | Bioenergetic medicine |
| Q92669148 | Breastfeeding predicts blood mitochondrial DNA content in adolescents |
| Q26747527 | Calcium-Sensing Receptors of Human Neural Cells Play Crucial Roles in Alzheimer's Disease |
| Q47887763 | Chronic traumatic encephalopathy-integration of canonical traumatic brain injury secondary injury mechanisms with tau pathology |
| Q26861082 | Common defects of mitochondria and iron in neurodegeneration and diabetes (MIND): a paradigm worth exploring |
| Q90699324 | Comparative functional genomic analysis of Alzheimer's affected and naturally aging brains |
| Q102369114 | Corticotropin-releasing hormone (CRH) alters mitochondrial morphology and function by activating the NF-kB-DRP1 axis in hippocampal neurons |
| Q33870189 | Cyclophilin D Promotes Brain Mitochondrial F1FO ATP Synthase Dysfunction in Aging Mice |
| Q55313950 | DANUBE: Data-driven meta-ANalysis using UnBiased Empirical distributions-applied to biological pathway analysis. |
| Q91938420 | Decoding the Role of Platelets and Related MicroRNAs in Aging and Neurodegenerative Disorders |
| Q90319593 | Diabetes and Alzheimer's Disease: A Link not as Simple as it Seems |
| Q57143976 | Distinguishing normal brain aging from the development of Alzheimer's disease: inflammation, insulin signaling and cognition |
| Q26827193 | Diverse molecular targets for therapeutic strategies in Alzheimer's disease |
| Q42218999 | Do astrocytes collaborate with neurons in spreading the "infectious" aβ and Tau drivers of Alzheimer's disease? |
| Q38116463 | Do we age because we have mitochondria? |
| Q64088857 | Dysfunctional Mitochondrial Bioenergetics and Synaptic Degeneration in Alzheimer Disease |
| Q57101020 | Dysregulated bile acid synthesis and dysbiosis are implicated in Western diet-induced systemic inflammation, microglial activation, and reduced neuroplasticity |
| Q58549216 | Early Life Stress and Epigenetics in Late-onset Alzheimer's Dementia: A Systematic Review |
| Q36291447 | Effect of aging on 5-hydroxymethylcytosine in brain mitochondria |
| Q64777150 | Effects of aging on brain volumes in healthy individuals across adulthood |
| Q38828060 | Energy metabolism and inflammation in brain aging and Alzheimer's disease. |
| Q37323658 | Enhanced Neuroplasticity by the Metabolic Enhancer Piracetam Associated with Improved Mitochondrial Dynamics and Altered Permeability Transition Pore Function. |
| Q57282791 | Enzyme Kinetics from Circular Dichroism of Insulin Reveals Mechanistic Insights into the Regulation of Insulin-degrading Enzyme |
| Q33623924 | Estrogen: a master regulator of bioenergetic systems in the brain and body |
| Q28079898 | Estrogenic Endocrine Disrupting Chemicals Influencing NRF1 Regulated Gene Networks in the Development of Complex Human Brain Diseases |
| Q53073786 | Evaluation of Animal Models by Comparison with Human Late-Onset Alzheimer's Disease. |
| Q47156198 | Fatty Acids, Antioxidants and Physical Activity in Brain Aging |
| Q38029575 | From mitochondrial dysfunction to amyloid beta formation: novel insights into the pathogenesis of Alzheimer's disease. |
| Q99239419 | Gene expression of serotonergic markers in peripheral blood mononuclear cells of patients with late-onset Alzheimer's disease |
| Q42363857 | Genetic Analysis of Mitochondrial Ribosomal Proteins and Cognitive Aging in Postmenopausal Women |
| Q47625969 | Hidden heterogeneity in Alzheimer's disease: Insights from genetic association studies and other analyses |
| Q48404424 | High-energy compounds promote physiological processing of Alzheimer's amyloid-β precursor protein and boost cell survival in culture |
| Q50161371 | Hippocampal Mutant APP and Amyloid Beta Induced Cognitive Decline, Dendritic Spine Loss, Defective Autophagy, Mitophagy and Mitochondrial Abnormalities in a Mouse Model of Alzheimer's Disease. |
| Q37551334 | Human platelets as a platform to monitor metabolic biomarkers using stable isotopes and LC-MS. |
| Q51758674 | Impact of Nitric Oxide Bioavailability on the Progressive Cerebral and Peripheral Circulatory Impairments During Aging and Alzheimer's Disease. |
| Q26782894 | Implications of glial nitric oxide in neurodegenerative diseases |
| Q36167749 | Induction of mitochondrial changes associated with oxidative stress on very long chain fatty acids (C22:0, C24:0, or C26:0)-treated human neuronal cells (SK-NB-E). |
| Q90080017 | Influence of PM2.5 Exposure Level on the Association between Alzheimer's Disease and Allergic Rhinitis: A National Population-Based Cohort Study |
| Q93197596 | Insights Into the Role of Mitochondrial Ion Channels in Inflammatory Response |
| Q36456888 | Is the mitochondrial outermembrane protein VDAC1 therapeutic target for Alzheimer's disease? |
| Q92570178 | Ketogenic Diet in Alzheimer's Disease |
| Q38022179 | Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes |
| Q34358832 | Melatonin regulates aging and neurodegeneration through energy metabolism, epigenetics, autophagy and circadian rhythm pathways |
| Q26992344 | Metabolomics of human brain aging and age-related neurodegenerative diseases |
| Q51764195 | MicroRNA-455-3p as a Potential Biomarker for Alzheimer's Disease: An Update. |
| Q28397259 | Mitochondria and reactive oxygen species: physiology and pathophysiology |
| Q38883083 | Mitochondria as a target for neuroprotection: implications for Alzheimer´s disease |
| Q42536278 | Mitochondria, diabetes, and Alzheimer's disease |
| Q36026916 | Mitochondria-targeted catalase reduces abnormal APP processing, amyloid β production and BACE1 in a mouse model of Alzheimer's disease: implications for neuroprotection and lifespan extension. |
| Q38126982 | Mitochondrial DNA methylation as a next-generation biomarker and diagnostic tool |
| Q36900007 | Mitochondrial DNA oxidative damage and repair in aging and Alzheimer's disease |
| Q43198180 | Mitochondrial Dysfunction and Chronic Disease: Treatment With Natural Supplements |
| Q38962796 | Mitochondrial Dysfunction and Synaptic Transmission Failure in Alzheimer's Disease |
| Q48881691 | Mitochondrial Proteome Changes Correlating with β-Amyloid Accumulation |
| Q26865358 | Mitochondrial abnormalities in Alzheimer's disease: possible targets for therapeutic intervention |
| Q38170006 | Mitochondrial dysfunction and NAD(+) metabolism alterations in the pathophysiology of acute brain injury |
| Q38607493 | Mitochondrial dysfunction: the missing link between aging and sporadic Alzheimer's disease |
| Q37460232 | Mitochondrial energy metabolism and redox signaling in brain aging and neurodegeneration |
| Q38570535 | Mitochondrial function in ageing: coordination with signalling and transcriptional pathways |
| Q36026546 | Mitochondrial- and endoplasmic reticulum-associated oxidative stress in Alzheimer's disease: from pathogenesis to biomarkers. |
| Q90462018 | Modulation of Cellular Biochemistry, Epigenetics and Metabolomics by Ketone Bodies. Implications of the Ketogenic Diet in the Physiology of the Organism and Pathological States |
| Q91722847 | Multigenerational metabolic profiling in the Michigan PBB registry |
| Q64868646 | Multivariate meta-analyses of mitochondrial complex I and IV in major depressive disorder, bipolar disorder, schizophrenia, Alzheimer disease, and Parkinson disease |
| Q90118206 | NBIA: a network-based integrative analysis framework - applied to pathway analysis |
| Q38745984 | Neuroketotherapeutics: A modern review of a century-old therapy |
| Q36817447 | Neuronal inputs and outputs of aging and longevity |
| Q38124394 | Neuronal toxicity of efavirenz: a systematic review |
| Q64120455 | Neuroprotective Activity of & Ethanolic Extracts in Scopolamine-Induced Amnesia in Swiss Albino Mice |
| Q92761855 | Neuroprotective Approach of Anti-Cancer Microtubule Stabilizers Against Tauopathy Associated Dementia: Current Status of Clinical and Preclinical Findings |
| Q38414169 | Neuroprotective and neurorestorative potential of propargylamine derivatives in ageing: focus on mitochondrial targets |
| Q37989403 | Non-classical membrane trafficking processes galore |
| Q46713723 | Of Energy and Entropy: The Ineluctable Impact of Aging in Old Age Dementia |
| Q42047971 | Oxaloacetate activates brain mitochondrial biogenesis, enhances the insulin pathway, reduces inflammation and stimulates neurogenesis. |
| Q38383273 | Oxaloacetate enhances neuronal cell bioenergetic fluxes and infrastructure. |
| Q35623258 | Oxidative Stress and Its Clinical Applications in Dementia |
| Q33555956 | Oxidative stress and mitochondrial dysfunction in Alzheimer's disease |
| Q41014821 | Phospholipid oxidation and carotenoid supplementation in Alzheimer's disease patients. |
| Q39421016 | Polyunsaturated fatty acids and endocannabinoids in health and disease. |
| Q35895780 | Promising Genetic Biomarkers of Preclinical Alzheimer's Disease: The Influence of APOE and TOMM40 on Brain Integrity |
| Q42265695 | Quantification of mitochondrial DNA copy number in suspected cancer patients by a well optimized ddPCR method |
| Q37315215 | RNA silencing of genes involved in Alzheimer's disease enhances mitochondrial function and synaptic activity |
| Q37586163 | Reduced VDAC1 protects against Alzheimer's disease, mitochondria, and synaptic deficiencies |
| Q50288922 | Role of Copper in the Onset of Alzheimer's Disease Compared to Other Metals. |
| Q27004644 | Role of methylglyoxal in Alzheimer's disease |
| Q38072757 | Role of platelets in neurodegenerative diseases: a universal pathophysiology |
| Q47569710 | Sex differences in the association of alcohol with cognitive decline and brain pathology in a cohort of octogenarians |
| Q36426980 | Sex hormone-related neurosteroids differentially rescue bioenergetic deficits induced by amyloid-β or hyperphosphorylated tau protein |
| Q38124259 | Sirtuins: from metabolic regulation to brain aging |
| Q90365059 | Systematic review of gene expression studies in people with Lewy Body Dementia |
| Q41844573 | Tau and neuron aging |
| Q37656554 | The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives |
| Q42948834 | The DNA repair enzyme apurinic/apyrimidinic endonuclease (Apex nuclease) 2 has the potential to protect against down-regulation of chondrocyte activity in osteoarthritis |
| Q58795119 | The Expanding Role of Ketogenic Diets in Adult Neurological Disorders |
| Q38837387 | The Mediterranean diet and age-related cognitive functioning: A systematic review of study findings and neuropsychological assessment methodology. |
| Q39776932 | The Mitochondria-Targeted Plastoquinone-Derivative SkQ1 Promotes Health and Increases Drosophila melanogaster Longevity in Various Environments |
| Q38843876 | The Proteasome and Oxidative Stress in Alzheimer's Disease |
| Q26795415 | The Role of Oxidative Damage in the Pathogenesis and Progression of Alzheimer's Disease and Vascular Dementia |
| Q36942402 | The effect of increased genetic risk for Alzheimer's disease on hippocampal and amygdala volume |
| Q36864568 | The influence of APOE and TOMM40 polymorphisms on hippocampal volume and episodic memory in old age |
| Q92852870 | Transmission Electron Microscopy Study of Mitochondria in Aging Brain Synapses |
| Q92603728 | Vitamin E and Alzheimer's disease: what do we know so far? |
| Q30850844 | What have novel imaging techniques revealed about metabolism in the aging brain? |
| Q36882294 | p53-dependent SIRT6 expression protects Aβ42-induced DNA damage |
| Q43210455 | β-Apptists and Tauists, it is time for a sermon from the book of biogenesis |
Search more.